Literature DB >> 27902653

Meningococcal Disease in Children in Argentina A 3-year Active Sentinel Hospital Surveillance Study.

Ángela Gentile1, Julia Bakir, María Rosa Agosti, Gabriela Ensinck, Hector Abate, Andrea Gajo Gane, Alejandro Santillán Iturres, Adriana Efron, Mabel Regueira, Ricardo Rüttimann.   

Abstract

BACKGROUND: Meningococcal disease (MD) is a medical emergency and a serious public health problem. As new meningococcal vaccines become available, MD surveillance is crucial to provide baseline epidemiologic data before implementing preventive measures. We estimated MD incidence and epidemiology in Argentina using hospital-based surveillance.
METHODS: Three-year prospective active surveillance in patients ≤15 years of age was conducted at 6 pediatric hospital sentinel units (March 2012 to February 2015).
RESULTS: Of 184,360 hospitalized patients, 1444 (0.78%) had suspected meningitis or MD. Of these, 268 (19%) presented probable acute bacterial meningitis or MD, 168 (63%) were culture positive and 51 (30%) tested positive for Neisseria meningitidis. Of 100 culture-negative cases, 30 had positive meningococcal polymerase chain reaction. Thirteen patients presented other uncommon MD manifestations, resulting in a total of 94 MD cases and an annual incidence of 5.1/10 hospitalized patients [95% confidence interval (CI): 4-6]. Fifty-four (57%) patients were males, 48% were <1 year of age and the median age was 12.5 months (1 month to 15 years). Clinical presentations were the following: meningococcemia and meningitis (37%), meningitis (30%), meningococcemia (16%), arthritis (10%), bacteremia (5%) and pneumonia (2%). Twenty-eight percent had complications. Nine children died (case fatality rate: 10%), and 8 had sequelae. Serogroups were identified for 84 isolates. Serogroup W was associated with age <1 year (odds ratio: 3.18; 95% CI: 1.14-8.99); meningococcemia was associated with mortality (P = 0.0038).
CONCLUSIONS: Highest rates of MD were observed among young infants. This study provides baseline data to estimate the impact of introducing meningococcal vaccines in Argentina.

Entities:  

Mesh:

Year:  2017        PMID: 27902653     DOI: 10.1097/INF.0000000000001429

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

1.  Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database.

Authors:  Yumi Matsumura
Journal:  Drug Healthc Patient Saf       Date:  2020-11-10

2.  Trends in vaccine investment in middle income countries.

Authors:  K Onishchenko; S Hill; M Wasserman; C Jones; M Moffatt; L Ruff; S J Pugh
Journal:  Hum Vaccin Immunother       Date:  2019-04-12       Impact factor: 3.452

3.  Estimation of the real burden of invasive meningococcal disease in Argentina.

Authors:  J A Gómez; P Wetzler Malbrán; G Vidal; M Seoane; N D Giglio
Journal:  Epidemiol Infect       Date:  2019-11-29       Impact factor: 2.451

4.  A meta-analytic evaluation of sex differences in meningococcal disease incidence rates in 10 countries.

Authors:  Manfred S Green; Naama Schwartz; Victoria Peer
Journal:  Epidemiol Infect       Date:  2020-10-02       Impact factor: 2.451

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.